Noxopharm Ltd. · ASX:NOX
Noxopharm — Reach Markets "Meet the CEOs" virtual event 2020
19 slides from Noxopharm's conference presentation, Jul 8, 2020
Slide 1: Corporate Presentation for the Reach Markets Virtual Event
For personal use only 8 July 2020 Sydney, Australia Corporate Presentation for the Reach Markets Virtual Event Sydney, 8 July 2020: Noxopharm (ASX:NOX) provides to shareholders and the market generally the corporate presentation for the Reach Markets “Meet the CEOs” virtual session at 12 noon today.
Slide 2: Noxopharm Limited (ASX:NOX) Reach Markets Meet the CEOs
For personal use only Noxopharm Limited (ASX:NOX) REACH MARKETS “ Meet the CEOs ”, 8 July 2020 Discover Develop Deliver NOXOPHARM LIMITED (ASX:NOX) 1
Slide 3: Disclaimer
Disclaimer For personal use only This presentation has been prepared by Noxopharm Limited (NOX or the Company). It should not Although the Company believes that the expectations reflected in the forward looking statements be considered as an offer or invitation to subscribe for, or purchase any shar
Slide 4: Veyonda
Veyonda®️ For personal use only NOX is focused on arguably the biggest prize in the pharma industry - a drug that makes the current generation of immuno-oncology (I-O) anti-cancer drugs work much better I-O drugs came to market 15 years ago to enormous acclaim and promise. However, that promise rema
Slide 5: Immuno-oncology drugs
Immuno-oncology drugs Next generation of anti-cancer drugs For personal use only Cancer represents a failure of the body’s immune system Cancers establish, grow and spread because they protect themselves from immune cells I-O drugs designed to tip balance back in favour of the immune system I-O drug
Slide 6: Converting COLD tumours to HOT tumours
Converting COLD tumours to HOT tumours The $multi-billion challenge For personal use only Source: Dana-Faber Cancer Institute NOXOPHARM LIMITED (ASX:NOX) 5
Slide 7: Strategy
Strategy For personal use only Step 1. Confirm in laboratory Veyonda®️ able to convert human tumours from COLD to HOT ☑️ Step 2. Phase 1 study (25 patients) confirming safety and providing proof-of- concept efficacy signals in cancer type with current poor I-O drug outcomes ☑️ Step 3. Conduct Phase
Slide 8: Prostate cancer: poor responder to I-O drugs
Prostate cancer: poor responder to I-O drugs For personal use only End stage cancer Surgery and/ Chemical Palliative Androgen receptor or local castration Chemotherapy & inhibitors therapy Rising PSA levels in blood radiotherapy therapy Hormone-sensitive Hormone-refractory Non-metastatic Metastatic
Slide 9: Substantial Global Unmet Need
Substantial Global Unmet Need1 For personal use only Prostate cancer is the fifth leading cause of Prostate Cancer – Mortality by Age Category (number of cases per 100,000 population) death in men worldwide 800 700 Responsible for estimated 360,000 deaths in 2018 600 500 Incidence Mortality from pro
Slide 10: Veyonda & DARRT
For personal use only Veyonda & DARRT NOXOPHARM LIMITED (ASX:NOX) 9
Slide 11: DARRT Explained
DARRT Explained For personal use only Direct Response DARRT (Direct and Abscopal Response to Radiotherapy) • DARRT is based on the idea of restoring the ability of the body’s immune system to fight the cancer • Low dose radiotherapy triggers an immune response in the irradiated tumours that contribu
Slide 12: DARRT-1 Phase 1 study
Veyonda® DARRT-1 Phase 1 study For personal use only 25 men enrolled with late-stage prostate cancer and treated Metastatic castration-resistant prostate cancer (mCRPC) Progressive disease No remaining standard treatment options Eligible for palliative radiotherapy (RT) for symptomatic relief Bone s
Slide 13: DARRT-1: PSA Response
DARRT-1: PSA Response For personal use only • Veyonda®️ in combination Over 50% with radiation therapy drop in PSA appeared to be safe and in 5/16 well-tolerated1 patients • In the 16* patients who were evaluable at 6 months1 9 patients lost to follow-up, died or withdrew from study PSA = prostate s
Slide 14: DARRT-1: Pain Response
DARRT-1: Pain Response For personal use only • Veyonda® in combination Over 30% with radiation therapy drop in pain appeared to be safe and levels in well-tolerated1 10/16 • In the 16* patients who were patients evaluable at 6 months1 4 patients became 9 patients lost to follow-up, died or withdrew
Slide 15: DARRT-1: Tumour Response
DARRT-1: Tumour Response For personal use only • In the 15* patients who were 6 months First part 400mg, Expansion part Overall 800mg & 1200mg All doses evaluable at 6 months1 follow-up (reported 12 Nov 2019) 1200mg (reported 2 Dec 2019) Overall • The Tumours stopped (RECIST1.1) N=10 N=5 N=15 growin
Slide 16: DARRT-2: Phase 2 study
DARRT-2: Phase 2 study • For personal use only Objectives: • The DARRT-2 is designed to provide the data that Commercial Partners are looking for • It also aims to satisfy the Regulatory Authorities • Building on the experience and data of DARRT-1 • Multinational. 2-3 continents. Approx. 200 men • M
Slide 17: Advanced prostate cancer: Attracting Significant Pharma Interest
Advanced prostate cancer: Attracting Significant Pharma Interest For personal use only Pfizer merger Novartis merger Novartis acquisition of Advanced Deal with Medivation (2016) with Endocyte (2018) Accelerator Applications (2018) Price US$14 billion US$2.1 billion US$3.9 billion XTANDI® (enzalutami
Slide 18: Key metrics
Key metrics For personal use only Market cap A$47M (6 July 2020) News Flow (next 6 -12months) * Commencement of DARRT-2 Share price A$0.22 (6 July 2020) * Progress in other clinical programs * Progress in drug pipeline Issued cap ~213M shares * Potential industry collaborations ongoing Recently clos
Slide 19: For further information
For personal use only For further information email: info@noxopharm.com web: www.noxopharm.com Discover Develop Deliver NOXOPHARM LIMITED (ASX:NOX) 18
Noxopharm — Reach Markets "Meet the CEOs" virtual event 2020 on 6ix